AI Threat and Casgevy Momentum: CRSP's Balancing Act

What happened

The Seeking Alpha article argues CRSP remains a long-term Buy based on Casgevy's 78% sequential Q2 sales growth, but the DeepValue master report had already highlighted that CRISPR itself has not recognized any product revenue from the Vertex hemoglobinopathy agreements, with total 1H26 revenue of only $11.6 million. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, though the article downplays near-term clinical impact; nevertheless, it adds another layer of uncertainty to an already crowded in vivo editing space. The master report rates CRSP a WAIT with conviction 2.5, citing a $2.364 billion cash cushion but requiring proof of Casgevy throughput and CTX310 de-risking before upgrading. At $49.60, the stock sits between the report's attractive entry of $44 and trim level of $62, reflecting the market's indecision between balance-sheet support and operating proof. The article's emphasis on sequential sales growth may mislead because CRISPR's benefit from the collaboration appears only as reduced collaboration expense, not recognized revenue, and the company still posted a $214.1 million net loss in 1H26.

Implication

The article's focus on Casgevy's sequential sales growth overlooks that CRISPR's accounting still shows no revenue from the Vertex partnership, so the economic benefit remains indirect and unlikely to justify a re-rating. Anthropic's entry into AI-driven gene editing, while not an immediate clinical threat, could divert funding and talent, potentially slowing CRISPR's pipeline progress. The master report's key checkpoints remain: by November 2026, updated Casgevy conversion metrics, and by January 2027, CTX310 data with a focused plan; failure on either would weaken the bull case. With the stock near the midpoint of the valuation range, risk-reward is balanced, but the attractive entry at $44 suggests patience for either a better price or a positive catalyst. Until filings show material economic recognition from the Vertex agreements or CTX310 demonstrates durability with a clear indication path, the stock is likely rangebound, and investors should monitor the next quarterly report and pipeline updates.

Thesis delta

The new information introduces a potential long-term competitive threat from AI-driven gene editing, but it does not change the near-term thesis that CRISPR lacks visible commercial economics and pipeline proof. The WAIT rating remains appropriate, and the AI angle adds a reason to be cautious about the durability of CRISPR's technology moat, though clinical impact is distant.